Specify a stock or a cryptocurrency in the search bar to get a summary
Sichuan Huiyu Pharmaceutical Co Ltd
688553Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor and injection drugs in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, sodium valproate concentrated solution, epirubicin hydrochloride, fulvestrant, milrinone, fluorouracil, sodium thiosulfate, zoledronic acid, zoledronic acid concentrated solution, cisatracurium besylate, bortezomib, octreotide acetate, doxorubicin, and palonosetron hydrochloride. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorportaed in 2010 and is headquartered in Neijiang, China. Address: Building 3, Neijiang, China, 641000
Analytics
WallStreet Target Price
–P/E ratio
24.9697Dividend Yield
1.33 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 688553
Dividend Analytics 688553
Dividend growth over 5 years
–Continuous growth
1 yearPayout Ratio 5 years average
53 %Dividend History 688553
Stock Valuation 688553
Financials 688553
Results | 2019 | Dynamics |